NASDAQ:CATB - Catabasis Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.96 -0.29 (-3.52 %)
(As of 05/19/2019 04:00 PM ET)
Previous Close$7.96
Today's Range$7.91 - $8.50
52-Week Range$3.60 - $17.60
Volume175,372 shs
Average Volume92,197 shs
Market Capitalization$91.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics based on safely metabolized and rationally targeted (SMART) linker drug discovery platform in the United States. The company's lead product candidate is Edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activate B cells, which is in Phase III clinical trial for the treatment of duchenne muscular dystrophy (DMD). It is also involved in developing CAT-5571 for the treatment of cystic fibrosis. Catabasis Pharmaceuticals, Inc. has a pre-clinical joint research collaboration agreement with Sarepta Therapeutics, Inc. to explore a combination drug treatment approach for DMD; and collaboration with the University of Texas Southwestern to study the potential benefits of edasalonexent treatment. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Receive CATB News and Ratings via Email

Sign-up to receive the latest news and ratings for CATB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CATB
CUSIPN/A
Phone617-349-1971

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$500,000.00
Book Value$4.34 per share

Profitability

Net Income$-25,870,000.00

Miscellaneous

Employees24
Market Cap$91.54 million
Next Earnings Date8/8/2019 (Estimated)
OptionableNot Optionable

Catabasis Pharmaceuticals (NASDAQ:CATB) Frequently Asked Questions

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

When did Catabasis Pharmaceuticals' stock split? How did Catabasis Pharmaceuticals' stock split work?

Catabasis Pharmaceuticals's stock reverse split on Monday, December 31st 2018. The 1-10 reverse split was announced on Monday, December 24th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 28th 2018. An investor that had 100 shares of Catabasis Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Catabasis Pharmaceuticals' earnings last quarter?

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) issued its earnings results on Tuesday, May, 14th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02. View Catabasis Pharmaceuticals' Earnings History.

When is Catabasis Pharmaceuticals' next earnings date?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, August 8th 2019. View Earnings Estimates for Catabasis Pharmaceuticals.

What price target have analysts set for CATB?

3 Wall Street analysts have issued 12-month price objectives for Catabasis Pharmaceuticals' stock. Their predictions range from $15.00 to $77.00. On average, they expect Catabasis Pharmaceuticals' share price to reach $36.6667 in the next year. This suggests a possible upside of 360.6% from the stock's current price. View Analyst Price Targets for Catabasis Pharmaceuticals.

What is the consensus analysts' recommendation for Catabasis Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catabasis Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catabasis Pharmaceuticals.

Has Catabasis Pharmaceuticals been receiving favorable news coverage?

Media headlines about CATB stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Catabasis Pharmaceuticals earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an impact on the company's share price in the next few days.

Who are some of Catabasis Pharmaceuticals' key competitors?

What other stocks do shareholders of Catabasis Pharmaceuticals own?

Who are Catabasis Pharmaceuticals' key executives?

Catabasis Pharmaceuticals' management team includes the folowing people:
  • Ms. Jill C. Milne, Co-Founder, CEO, Pres & Director (Age 51)
  • Dr. Andrew J. Nichols, Chief Scientific Officer (Age 58)
  • Dr. Joanne M. Donovan, Chief Medical Officer & Sr. VP of Clinical Devel. (Age 62)
  • Mr. Noah Clauser, VP of Fin. & Controller
  • Ms. Deirdre A. Cunnane, Chief Legal Officer & Treasurer (Age 54)

When did Catabasis Pharmaceuticals IPO?

(CATB) raised $60 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 4,300,000 shares at $13.00-$15.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and Oppenheimer and Wedbush PacGrow were co-managers.

Who are Catabasis Pharmaceuticals' major shareholders?

Catabasis Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Federated Investors Inc. PA (19.04%), Dimensional Fund Advisors LP (1.29%), Renaissance Technologies LLC (1.08%), Oppenheimer & Co. Inc. (0.80%), Oxford Asset Management LLP (0.65%) and RMB Capital Management LLC (0.56%). View Institutional Ownership Trends for Catabasis Pharmaceuticals.

Which major investors are buying Catabasis Pharmaceuticals stock?

CATB stock was purchased by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, Dimensional Fund Advisors LP, Renaissance Technologies LLC, Oxford Asset Management LLP, RMB Capital Management LLC, BlackRock Inc., Oppenheimer & Co. Inc. and Virtu Financial LLC. View Insider Buying and Selling for Catabasis Pharmaceuticals.

How do I buy shares of Catabasis Pharmaceuticals?

Shares of CATB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Catabasis Pharmaceuticals' stock price today?

One share of CATB stock can currently be purchased for approximately $7.96.

How big of a company is Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals has a market capitalization of $91.54 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-25,870,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Catabasis Pharmaceuticals employs 24 workers across the globe.

What is Catabasis Pharmaceuticals' official website?

The official website for Catabasis Pharmaceuticals is http://www.catabasis.com.

How can I contact Catabasis Pharmaceuticals?

Catabasis Pharmaceuticals' mailing address is One Kendall Square Bldg. 1400E Suite B14202, Cambridge MA, 02139. The biotechnology company can be reached via phone at 617-349-1971 or via email at [email protected]


MarketBeat Community Rating for Catabasis Pharmaceuticals (NASDAQ CATB)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  352 (Vote Outperform)
Underperform Votes:  230 (Vote Underperform)
Total Votes:  582
MarketBeat's community ratings are surveys of what our community members think about Catabasis Pharmaceuticals and other stocks. Vote "Outperform" if you believe CATB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CATB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 5/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel